Track MetaStat, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

MetaStat, Inc. MTST Open MetaStat, Inc. in new tab

0.000600 USD
EPS
-0.10
P/B
0.00
Beta
317.82
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
EPS-0.10
Book Value-0.26
Price to Book0.00
% Insiders1.568%

DCF Valuation

Tweak assumptions to recompute fair value for MetaStat, Inc. (MTST)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

MetaStat, Inc. Logo MetaStat, Inc. Analysis (MTST)

United States Health Care Official Website Stock

Is MetaStat, Inc. a good investment? MetaStat, Inc. (MTST) is currently trading at 0.000600 USD.

Investor FAQ

Does MetaStat, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is MetaStat, Inc.?

MetaStat, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

Company Profile

MetaStat, Inc., a precision medicine company, focuses on discovering and developing therapeutic and diagnostic treatment solutions for cancer patients. The company is developing novel drug candidates and companion diagnostic tests that target the MENA pathway. Its product candidates include MENA diagnostic assay, a tissue-based quantitative immunofluorescence test that measures expression of the pro-metastatic MENA protein splice-variant; companion diagnostic to predict RTK inhibitor drug responses and anti-microtubule drug responses; liquid blood-based biopsy to enhance cancer diagnosis and optimize patient care; MetaSite Breast assay, an immunohistochemistry test that measures micro-anatomical intravasat at blood vessels within the tumor microenvironment ion sites; and prognostic diagnostic to predict risk of cancer metastasis. The company's therapeutic targets a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer. MetaStat, Inc. is based in Boston, Massachusetts.

Exchange Ticker
PNK (United States) MTST

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion